The Genesis Inherited Cancer Panel is a targeted semiconductor sequencing assay designed to enumerate genes associated with an increased risk of developing hereditary cancers. The panel has undergone extensive research and development time and is expertly curated using the latest research community consortia findings. Patient profiling of these 53 genes provides the physician with a comprehensive clinical patient profile, revealing both single nucleotide variants (SNVs) and insertion-deletion mutations (indels).